Support Your Metabolism with Clinically-Studied Ingredients

Mitolyn — 6 plant-based nutrients to boost mitochondrial health, energy & natural fat burning.

★★★★★ 127,000+ customers · 90-day money-back guarantee

Dr. Jack Vu, MD

Family Medicine Long Beach, CA Male

NPI: 1083885826

Total Payments

$257,281

2024 Payments

$6,874

Companies

Transactions

Medicare Patients

872

Medicare Billing

$42,688

Payment Breakdown by Category

Research$255,099 (99.2%)

Travel$1,859 (0.7%)

Food & Beverage$323.39 (0.1%)

Payments by Nature

Nature of Payment	Amount	Transactions	Share
Unspecified	$255,099	13	99.2%
Travel and Lodging	$1,859	6	0.7%
Food and Beverage	$323.39	6	0.1%

Payments by Type

Research

$255,099

13 transactions

General

$2,182

12 transactions

Top Paying Companies

Company	Total	Records	Latest Year
Overseas Pharmaceuticals LLC	$241,557	1	$0 (2022)
Eli Lilly and Company	$13,428	17	$0 (2024)
Novavax Inc	$2,183	6	$0 (2023)
Janssen Pharmaceuticals, Inc	$113.43	1	$0 (2017)

Payment History by Year

Year	Amount	Transactions	Top Company
2024	$6,874	2	Eli Lilly and Company ($6,874)
2023	$2,183	6	Novavax Inc ($2,183)
2022	$248,110	16	Overseas Pharmaceuticals LLC ($241,557)
2017	$113.43	1	Janssen Pharmaceuticals, Inc ($113.43)

All Payment Transactions

25 individual payment records from CMS Open Payments

Date	Company	Product	Nature	Form	Amount	Type
09/27/2024	Eli Lilly and Company	—	—	Cash or cash equivalent	$1,000.00	Research
Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY
09/23/2024	Eli Lilly and Company	—	—	Cash or cash equivalent	$5,874.00	Research
Study: OBSTRUCTIVE SLEEP APNEA MASTER PROTOCOL GPIF: A STUDY OF TIRZEPATIDE (LY3298176) IN PARTICIPANTS WITH OBSTRUCTIVE SLEEP APNEA (SURMOUNT-OSA)
10/20/2023	Novavax Inc	—	—	In-kind items and services	$1,433.28	Research
Study: A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines
10/20/2023	Novavax Inc	—	—	In-kind items and services	$190.97	Research
Study: A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines
10/20/2023	Novavax Inc	—	—	In-kind items and services	$182.03	Research
Study: A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines
10/20/2023	Novavax Inc	—	—	In-kind items and services	$178.38	Research
Study: A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines
10/20/2023	Novavax Inc	—	—	In-kind items and services	$166.57	Research
Study: A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines
10/20/2023	Novavax Inc	—	—	In-kind items and services	$31.61	Research
Study: A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines
11/22/2022	Overseas Pharmaceuticals LLC	—	—	Cash or cash equivalent	$241,556.75	Research
Study: Ibuprofen Modified-Release Tablets
10/12/2022	Eli Lilly and Company	—	Travel and Lodging	In-kind items and services	$757.11	General
10/12/2022	Eli Lilly and Company	—	Travel and Lodging	In-kind items and services	$383.00	General
10/12/2022	Eli Lilly and Company	—	Travel and Lodging	In-kind items and services	$360.24	General
10/12/2022	Eli Lilly and Company	—	Travel and Lodging	In-kind items and services	$208.65	General
10/12/2022	Eli Lilly and Company	—	Food and Beverage	In-kind items and services	$135.73	General
10/12/2022	Eli Lilly and Company	—	Travel and Lodging	In-kind items and services	$128.00	General
10/12/2022	Eli Lilly and Company	—	Food and Beverage	In-kind items and services	$25.74	General
10/12/2022	Eli Lilly and Company	—	Travel and Lodging	In-kind items and services	$21.76	General
10/12/2022	Eli Lilly and Company	—	Food and Beverage	In-kind items and services	$20.30	General
10/12/2022	Eli Lilly and Company	—	Food and Beverage	In-kind items and services	$15.59	General
10/12/2022	Eli Lilly and Company	—	Food and Beverage	In-kind items and services	$12.60	General
08/08/2022	Eli Lilly and Company	—	—	In-kind items and services	$1,303.00	Research
Study: OBSTRUCTIVE SLEEP APNEA MASTER PROTOCOL GPIF: A STUDY OF TIRZEPATIDE (LY3298176) IN PARTICIPANTS WITH OBSTRUCTIVE SLEEP APNEA (SURMOUNT-OSA)
06/30/2022	Eli Lilly and Company	—	—	In-kind items and services	$2,112.00	Research
Study: OBSTRUCTIVE SLEEP APNEA MASTER PROTOCOL GPIF: A STUDY OF TIRZEPATIDE (LY3298176) IN PARTICIPANTS WITH OBSTRUCTIVE SLEEP APNEA
06/08/2022	Eli Lilly and Company	—	—	In-kind items and services	$933.00	Research
Study: OBSTRUCTIVE SLEEP APNEA MASTER PROTOCOL GPIF A STUDY OF TIRZEPATIDE (LY3298176) IN PARTICIPANTS WITH OBSTRUCTIVE SLEEP APNEA
04/29/2022	Eli Lilly and Company	—	—	In-kind items and services	$137.00	Research
Study: RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN
02/15/2017	Janssen Pharmaceuticals, Inc	XARELTO (Drug)	Food and Beverage	In-kind items and services	$113.43	General
Category: Cardiovascular & Metabolism

Research Studies & Clinical Trials

Study Name	Company	Amount	Records
Ibuprofen Modified-Release Tablets	Overseas Pharmaceuticals LLC	$241,557	1
OBSTRUCTIVE SLEEP APNEA MASTER PROTOCOL GPIF: A STUDY OF TIRZEPATIDE (LY3298176) IN PARTICIPANTS WITH OBSTRUCTIVE SLEEP APNEA (SURMOUNT-OSA)	Eli Lilly and Company	$7,177	2
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines	Novavax Inc	$2,183	6
OBSTRUCTIVE SLEEP APNEA MASTER PROTOCOL GPIF: A STUDY OF TIRZEPATIDE (LY3298176) IN PARTICIPANTS WITH OBSTRUCTIVE SLEEP APNEA	Eli Lilly and Company	$2,112	1
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY	Eli Lilly and Company	$1,000	1
OBSTRUCTIVE SLEEP APNEA MASTER PROTOCOL GPIF A STUDY OF TIRZEPATIDE (LY3298176) IN PARTICIPANTS WITH OBSTRUCTIVE SLEEP APNEA	Eli Lilly and Company	$933.00	1
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN	Eli Lilly and Company	$137.00	1

Medicare Billing by Year

Year	Procedures	Beneficiaries	Services	Submitted	Medicare Paid
2022	3	87	87	$16,900	$4,782
2021	8	344	406	$59,600	$20,676
2020	12	441	526	$56,415	$17,231

Total Patients

872

Total Services

1,019

Medicare Billing

$42,688

Procedure Codes

All Medicare Procedures & Services

23 procedure records from CMS Medicare Utilization

HCPCS	Description	Setting	Year	Patients	Services	Charges	Medicare Paid	Ratio
99213	Established patient office or other outpatient visit, 20-29 minutes	Office	2022	50	50	$10,150	$2,710	26.7%
99214	Established patient office or other outpatient visit, 30-39 minutes	Office	2022	23	23	$6,624	$2,024	30.6%
81002	Urinalysis, manual test	Office	2022	14	14	$126.00	$48.59	38.6%
99213	Established patient outpatient visit, total time 20-29 minutes	Office	2021	184	195	$38,103	$13,752	36.1%
99214	Established patient outpatient visit, total time 30-39 minutes	Office	2021	42	43	$11,961	$4,418	36.9%
99203	New patient outpatient visit, total time 30-44 minutes	Office	2021	21	21	$5,215	$1,498	28.7%
71046	X-ray of chest, 2 views	Office	2021	13	13	$1,403	$377.28	26.9%
96372	Injection beneath the skin or into muscle for therapy, diagnosis, or prevention	Office	2021	27	30	$1,800	$360.08	20.0%
81002	Urinalysis, manual test	Office	2021	33	37	$325.00	$128.76	39.6%
93000	Routine ekg using at least 12 leads including interpretation and report	Office	2021	11	11	$681.00	$120.51	17.7%
J0696	Injection, ceftriaxone sodium, per 250 mg	Office	2021	13	56	$112.00	$21.23	19.0%
99213	Established patient office or other outpatient visit, typically 15 minutes	Office	2020	154	162	$26,730	$8,207	30.7%
99214	Established patient office or other outpatient, visit typically 25 minutes	Office	2020	60	61	$14,701	$4,512	30.7%
99203	New patient office or other outpatient visit, typically 30 minutes	Office	2020	37	37	$8,954	$2,956	33.0%
96372	Injection beneath the skin or into muscle for therapy, diagnosis, or prevention	Office	2020	38	45	$2,700	$480.36	17.8%
71046	X-ray of chest, 2 views	Office	2020	18	19	$1,349	$439.18	32.6%
93000	Routine ekg using at least 12 leads including interpretation and report	Office	2020	14	15	$585.00	$202.24	34.6%
94640	Respiratory inhaled pressure or nonpressure treatment to relieve airway obstruction or for sputum specimen	Office	2020	16	16	$720.00	$162.19	22.5%
81002	Urinalysis, manual test	Office	2020	43	44	$308.00	$152.35	49.5%
82962	Blood glucose (sugar) test performed by hand-held instrument	Office	2020	13	13	$104.00	$42.29	40.7%
36415	Insertion of needle into vein for collection of blood sample	Office	2020	14	14	$84.00	$41.64	49.6%
J0696	Injection, ceftriaxone sodium, per 250 mg	Office	2020	18	80	$160.00	$34.31	21.4%
J7620	Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme	Office	2020	16	20	$20.00	$1.48	7.4%

About Dr. Jack Vu, MD

Dr. Jack Vu, MD is a Family Medicine healthcare provider based in Long Beach, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/20/2008. The National Provider Identifier (NPI) number assigned to this provider is 1083885826.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jack Vu, MD has received a total of $257,281 in payments from pharmaceutical and medical device companies, with $6,874 received in 2024. These payments were reported across 25 transactions from 4 companies. The most common payment nature is "" ($255,099).

As a Medicare-enrolled provider, Vu has provided services to 872 Medicare beneficiaries, totaling 1,019 services with total Medicare billing of $42,688. Data is available for 3 years (2020–2022), covering 23 distinct procedure/service records.

16,000 Woodworking Plans

Step-by-step blueprints for any project. Beginner to expert.

Detailed schematics Cutting lists & materials Lifetime access — $67

★★★★★ 60-day guarantee

Get Instant Access

Practice Information

Specialty Family Medicine
Location Long Beach, CA
Active Since 03/20/2008
Last Updated 03/17/2018
Taxonomy Code 207Q00000X
Entity Type Individual
NPI Number 1083885826

Products in Payments

XARELTO (Drug) $113.43

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.